CMS subsidiary Dermavon gets China approval for Lumirix atopic dermatitis
CMS says its subsidiary Dermavon has received approval in China for Lumirix for an additional indication of atopic dermatitis.
SHENZHEN, CHINA, Sept.
03, 2026 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listin…